JP2020080650A - Sleepiness inhibitor and food and beverage for inhibiting sleepiness - Google Patents
Sleepiness inhibitor and food and beverage for inhibiting sleepiness Download PDFInfo
- Publication number
- JP2020080650A JP2020080650A JP2018214514A JP2018214514A JP2020080650A JP 2020080650 A JP2020080650 A JP 2020080650A JP 2018214514 A JP2018214514 A JP 2018214514A JP 2018214514 A JP2018214514 A JP 2018214514A JP 2020080650 A JP2020080650 A JP 2020080650A
- Authority
- JP
- Japan
- Prior art keywords
- drowsiness
- isomaltulose
- sleepiness
- food
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010041349 Somnolence Diseases 0.000 title claims abstract description 45
- 235000013305 food Nutrition 0.000 title claims description 16
- 208000032140 Sleepiness Diseases 0.000 title abstract description 6
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 230000037321 sleepiness Effects 0.000 title abstract description 6
- 235000013361 beverage Nutrition 0.000 title description 5
- 230000002401 inhibitory effect Effects 0.000 title 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 description 19
- 235000000346 sugar Nutrition 0.000 description 14
- 239000013078 crystal Substances 0.000 description 9
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- -1 sucrose fatty acid ester Chemical class 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 229960001948 caffeine Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- SVBWNHOBPFJIRU-UHFFFAOYSA-N 1-O-alpha-D-Glucopyranosyl-D-fructose Natural products OC1C(O)C(O)C(CO)OC1OCC1(O)C(O)C(O)C(O)CO1 SVBWNHOBPFJIRU-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001622809 Serratia plymuthica Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- NMXLJRHBJVMYPD-IPFGBZKGSA-N trehalulose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O)CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NMXLJRHBJVMYPD-IPFGBZKGSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/62—Palatinose, isomaltulose
Abstract
Description
本発明は、眠気抑制剤及び眠気抑制用飲食品に関する。 The present invention relates to a drowsiness suppressor and a food or drink for suppressing drowsiness.
仕事、勉強等の作業中に感じる眠気は、作業効率の低下を引き起こす。眠気を防止又は解消する成分としては、従来カフェインが知られている。カフェインには中枢神経を興奮させて精神機能を更新させる作用があることが知られており、例えば特許文献１には、カフェイン及び所定の成分を含有する眠気防止剤が開示されている。 The drowsiness felt during work such as work and study causes a decrease in work efficiency. Caffeine has been conventionally known as a component for preventing or eliminating drowsiness. It is known that caffeine excites the central nervous system to renew mental functions, and for example, Patent Document 1 discloses a drowsiness preventive agent containing caffeine and a predetermined component.
一方、消費者の中にはカフェインの過剰摂取を敬遠する者もいるため、眠気を抑制する効果を有する新たな成分が求められている。 On the other hand, since some consumers refrain from excessive intake of caffeine, new components having an effect of suppressing drowsiness are required.
本発明の一側面は、新規な眠気抑制剤を提供することを目的とする。 One aspect of the present invention aims to provide a novel drowsiness suppressant.
本発明は、第１の側面として、イソマルツロースを有効成分として含有する、眠気抑制剤を提供する。 As a first aspect, the present invention provides a drowsiness suppressant containing isomaltulose as an active ingredient.
本発明は、他の側面として、イソマルツロースを有効成分として含有する、眠気抑制用飲食品を提供する。 As another aspect, the present invention provides a food and drink for suppressing drowsiness, which contains isomaltulose as an active ingredient.
本発明の一側面によれば、新規な眠気抑制剤を提供することができる。 According to one aspect of the present invention, a novel drowsiness suppressor can be provided.
以下、本発明の実施形態を説明するが、本発明は以下の実施形態に限定されるものではない。 Hereinafter, embodiments of the present invention will be described, but the present invention is not limited to the following embodiments.
本明細書における「眠気抑制剤」は、眠気の発生を事前に抑制する作用、及び発生した眠気を解消する作用の少なくとも１種以上の作用を有するものである。すなわち、本明細書における「眠気抑制剤」は、「眠気解消剤」ということもできる。 The “drowsiness inhibitor” in the present specification has at least one action of suppressing the sleepiness in advance and eliminating the sleepiness that has occurred. That is, the “drowsiness inhibitor” in the present specification can also be referred to as “drowsiness eliminating agent”.
本発明の一実施形態に係る眠気抑制剤は、イソマルツロースを含有する。 The drowsiness suppressor according to one embodiment of the present invention contains isomaltulose.
イソマルツロースは、グルコースとフルクトースとがα−１，６結合した二糖類であり、スクロースの構造異性体である。イソマルツロースは、例えば、天然の蜂蜜中に見出される。工業的には、イソマルツロースは、プロタミノバクター・ルブラム（Ｐｒｏｔａｍｉｎｏｂａｃｔｅｒ ｒｕｂｒｕｍ）、セラチア・プリムチカ（Ｓｅｒｒａｔｉａ ｐｌｙｍｕｔｈｉｃａ）等の細菌に由来するα−グルコシルトランスフェラーゼをスクロースに作用させることにより製造される。 Isomaltulose is a disaccharide in which glucose and fructose are linked by α-1,6, and is a structural isomer of sucrose. Isomaltulose is found, for example, in natural honey. Industrially, isomaltulose is produced by reacting sucrose with α-glucosyltransferase derived from a bacterium such as Protaminobacterium rubrum, Serratia plymuthica.
イソマルツロース（ｉｓｏｍａｌｔｕｌｏｓｅ）は、パラチノース（ｐａｌａｔｉｎｏｓｅ）とも称される。なお、「パラチノース／ＰＡＬＡＴＩＮＯＳＥ」は、三井製糖株式会社の登録商標である。 Isomaltulose is also called palatinose. “Palatinose/PALATINOSE” is a registered trademark of Mitsui Sugar Co., Ltd.
眠気抑制剤は、イソマルツロースのみからなっていてよく、イソマルツロースを含有する組成物であってもよい。 The drowsiness suppressor may consist of isomaltulose alone, or may be a composition containing isomaltulose.
眠気抑制剤が組成物である場合、これに含まれるイソマルツロースは、イソマルツロース単体として含有されてもよく、いくつかの糖類を含有する市販のイソマルツロース製剤として含有されてもよい。イソマルツロース製剤は、イソマルツロースの他に、トレハロース等のその他の糖類を含むことがある。 When the drowsiness suppressant is a composition, the isomaltulose contained therein may be contained as a simple substance of isomaltulose, or may be contained as a commercially available isomaltulose preparation containing some sugars. The isomaltulose preparation may contain other sugars such as trehalose in addition to isomaltulose.
イソマルツロースは、結晶粒子として眠気抑制剤に含有されてもよいし、顆粒状粒子として含有されてもよい。顆粒状粒子は、例えば、イソマルツロースの複数の結晶粒子の集合体と、非晶質の糖分とを含み、該糖分が結晶粒子の集合体に内包されている、（球状）粒子であってもよい。このような顆粒状粒子は、例えば、イソマルツロースと非晶質の糖分とを含む糖液からイソマルツロースの結晶粒子を析出させ、該結晶粒子を含む糖液をスプレードライする方法により、得ることができる。あるいは、上記糖液を加熱しながらこれに剪断力を加えてイソマルツロースの結晶核を析出させ、該結晶核を含む混合物を冷却する方法により、イソマルツロースを含む顆粒状の粒子を得ることもできる。上記の糖液は、例えば、スクロースに酵素を作用させることにより、得ることができる。この場合、糖液及び得られる顆粒状粒子は、トレハロース、フルクトース、グルコース、スクロース及びイソマルトース等を非晶質の糖分として含む。顆粒状粒子は、特開２０１２−１７９０４５号公報等に記載されている固形物であってもよい。 Isomaltulose may be contained as crystal particles in the drowsiness suppressor, or may be contained as granular particles. The granular particles are, for example, (spherical) particles containing an aggregate of a plurality of isomaltulose crystal particles and an amorphous sugar component, and the sugar component being encapsulated in the aggregate of crystal particles. Good. Such granular particles are obtained, for example, by a method of precipitating isomaltulose crystal particles from a sugar solution containing isomaltulose and an amorphous sugar and spray-drying the sugar solution containing the crystal particles. be able to. Alternatively, while heating the sugar solution, a shearing force is applied to the sugar solution to precipitate a crystal nucleus of isomaltulose, and a mixture containing the crystal nucleus is cooled to obtain granular particles containing isomaltulose. You can also The above sugar solution can be obtained, for example, by reacting an enzyme with sucrose. In this case, the sugar solution and the resulting granular particles contain trehalose, fructose, glucose, sucrose, isomaltose and the like as amorphous sugars. The granular particles may be solid substances described in JP 2012-179045 A or the like.
眠気抑制剤がイソマルツロースの結晶粒子を含有する場合、結晶粒子のメジアン径は、レーザー回析粒度分布測定により測定したときに、例えば、５〜５０μｍであってよい。眠気抑制剤がイソマルツロースを含む顆粒状粒子を含有する場合、顆粒状粒子のメジアン径は、レーザー回析粒度分布測定により測定したときに、例えば、６０〜３００μｍ、又は８０〜２００μｍであってよい。顆粒状粒子におけるイソマルツロースの含有割合は、例えば７０質量％以上であり、好ましくは７０〜９５質量％である。 When the drowsiness suppressor contains isomaltulose crystal particles, the median diameter of the crystal particles may be, for example, 5 to 50 μm as measured by laser diffraction particle size distribution measurement. When the drowsiness suppressor contains granular particles containing isomaltulose, the median diameter of the granular particles is, for example, 60 to 300 μm, or 80 to 200 μm, when measured by laser diffraction particle size distribution measurement. Good. The content ratio of isomaltulose in the granular particles is, for example, 70% by mass or more, and preferably 70 to 95% by mass.
眠気抑制剤がイソマルツロースを含有する組成物である場合、イソマルツロースの含有量は、眠気抑制剤全量を基準として、好ましくは１５質量％以上であり、より好ましくは２０質量％以上であり、更に好ましくは２５質量％以上であり、また、好ましくは１００質量％未満であり、より好ましくは７０質量％以下である。 When the drowsiness suppressor is a composition containing isomaltulose, the content of isomaltulose is preferably 15% by mass or more, and more preferably 20% by mass or more, based on the total amount of the drowsiness suppressor. , More preferably 25 mass% or more, preferably less than 100 mass%, more preferably 70 mass% or less.
眠気抑制剤がイソマルツロースを含有する組成物である場合、眠気抑制剤は、イソマルツロース以外のその他の原料を含むことができる。その他の原料は、トレハロース、フルクトース、グルコース、スクロース、イソマルトース、トレハルロース等の糖類であってよい。その他の原料の含有量は、眠気抑制剤全量を基準として、０質量％超３０質量％以下であってよい。 When the drowsiness suppressor is a composition containing isomaltulose, the drowsiness suppressor may include other raw materials other than isomaltulose. Other raw materials may be sugars such as trehalose, fructose, glucose, sucrose, isomaltose, trehalulose. The content of other raw materials may be more than 0% by mass and 30% by mass or less based on the total amount of the drowsiness suppressor.
眠気抑制剤は、固体（粉末、顆粒等）、液体（溶液、懸濁液等）、ペースト等のいずれの形状であってもよく、散剤、丸剤、顆粒剤、錠剤、カプセル剤、トローチ剤、液剤、懸濁剤等のいずれの剤形であってもよい。 The drowsiness suppressor may be in any form such as solid (powder, granules, etc.), liquid (solution, suspension, etc.), paste, etc., and is a powder, pill, granule, tablet, capsule, troche. It may be in any form such as a solution, a suspension or the like.
眠気抑制剤においては、経腸投与等の非経口投与がされてもよいが、経口投与されることが好ましい。 The drowsiness suppressant may be administered parenterally, such as enterally, but is preferably orally administered.
投与量の一例として、例えば、イソマルツロースが１回当たり１５ｇ以上となるように投与されるのが好ましく、２０ｇ以上となるように投与されるのがより好ましく、２５ｇ以上となるように投与されるのが更に好ましい。また、イソマルツロースが１回当たり５０ｇ以下となるように投与されるのが好ましく、４５ｇ以下となるように投与されるのがより好ましく、４０ｇ以下となるように投与されるのが更に好ましい。 As an example of a dose, for example, isomaltulose is preferably administered at a dose of 15 g or more per dose, more preferably at 20 g or more, more preferably at 25 g or more. Is more preferable. Further, isomaltulose is preferably administered at a dose of 50 g or less, more preferably at a dose of 45 g or less, still more preferably at a dose of 40 g or less.
眠気抑制剤は、飲食品（食品組成物）、医薬部外品又は医薬品として用いることができる。眠気抑制剤は、好ましくは飲食品として用いられる。 The drowsiness suppressor can be used as a food or drink (food composition), a quasi drug, or a drug. The drowsiness inhibitor is preferably used as a food or drink.
一実施形態に係る眠気抑制用飲食品は、イソマルツロースを有効成分として含有する。本実施形態に係る眠気抑制用飲食品は、上述した眠気抑制剤を含有する飲食品であってもよい。 The food/drink product for suppressing drowsiness according to one embodiment contains isomaltulose as an active ingredient. The food/drink for drowsiness control according to the present embodiment may be a food/drink containing the above-described drowsiness suppressor.
眠気抑制用飲食品は、イソマルツロース及び上述したその他の原料に加えて、飲食品、医薬部外品又は医薬品に使用可能な素材を更に含有してもよい。飲食品、医薬部外品又は医薬品に使用可能な素材としては、特に制限されるものではないが、例えば、アミノ酸、タンパク質、炭水化物、油脂、甘味料、ミネラル、ビタミン、香料、賦形剤、結合剤、滑沢剤、崩壊剤、乳化剤、界面活性剤、基剤、溶解補助剤、懸濁化剤等が挙げられる。 The food or drink for suppressing drowsiness may further contain a material usable for food and drink, quasi drugs, or drugs, in addition to isomaltulose and the other raw materials described above. Materials usable for food and drink, quasi-drugs, or pharmaceuticals are not particularly limited, and examples thereof include amino acids, proteins, carbohydrates, oils and fats, sweeteners, minerals, vitamins, flavors, excipients, and binders. Examples include agents, lubricants, disintegrants, emulsifiers, surfactants, bases, solubilizing agents, suspending agents and the like.
タンパク質としては、例えば、ミルクカゼイン、ホエイ、大豆タンパク、小麦タンパク、卵白等が挙げられる。炭水化物としては、例えば、コーンスターチ、セルロース、α化デンプン、小麦デンプン、米デンプン、馬鈴薯デンプン等が挙げられる。油脂としては、例えば、サラダ油、コーン油、大豆油、ベニバナ油、オリーブ油、パーム油等が挙げられる。甘味料としては、例えば、ブドウ糖、ショ糖、果糖、ブドウ糖果糖液糖、果糖ブドウ糖液糖等の糖類、キシリトール、エリスリトール、マルチトール等の糖アルコール、スクラロース、アスパルテーム、サッカリン、アセスルファムＫ等の人工甘味料、ステビア甘味料などが挙げられる。ミネラルとしては、例えば、カルシウム、カリウム、リン、ナトリウム、マンガン、鉄、亜鉛、マグネシウム、これらの塩類等が挙げられる。ビタミンとしては、例えば、ビタミンＥ、ビタミンＣ、ビタミンＡ、ビタミンＤ、ビタミンＢ類、ビオチン、ナイアシン等が挙げられる。賦形剤としては、例えば、デキストリン、デンプン、乳糖、結晶セルロース等が挙げられる。結合剤としては、例えば、ポリビニルアルコール、ゼラチン、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロースナトリウム、ポリビニルピロリドン等が挙げられる。滑沢剤としては、例えば、ステアリン酸マグネシウム、ステアリン酸カルシウム、タルク等が挙げられる。崩壊剤としては、例えば、結晶セルロース、寒天、ゼラチン、炭酸カルシウム、炭酸水素ナトリウム、デキストリン等が挙げられる。乳化剤又は界面活性剤としては、例えば、ショ糖脂肪酸エステル、クエン酸、乳酸、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ソルビタン脂肪酸エステル、プロピレングリコール脂肪酸エステル、レシチン等が挙げられる。基剤としては、例えば、セトステアリルアルコール、ラノリン、ポリエチレングリコール等が挙げられる。溶解補助剤としては、例えば、ポリエチレングリコール、プロピレングリコール、炭酸ナトリウム、クエン酸ナトリウム等が挙げられる。懸濁化剤としては、例えば、モノステアリン酸グリセリン、ポリビニルアルコール、ポリビニルピロリドン、メチルセルロース、ヒドロキシメチルセルロース、アルギン酸ナトリウム等が挙げられる。これらは１種単独で、又は２種以上を組み合わせて使用されてもよい。 Examples of the protein include milk casein, whey, soybean protein, wheat protein, egg white and the like. Examples of carbohydrates include corn starch, cellulose, pregelatinized starch, wheat starch, rice starch, potato starch and the like. Examples of fats and oils include salad oil, corn oil, soybean oil, safflower oil, olive oil, palm oil and the like. Examples of the sweetener include sugars such as glucose, sucrose, fructose, high-fructose corn syrup, high-fructose corn syrup, sugar alcohols such as xylitol, erythritol and maltitol, sucralose, aspartame, saccharin and artificial sweeteners such as acesulfame K. And stevia sweeteners. Examples of minerals include calcium, potassium, phosphorus, sodium, manganese, iron, zinc, magnesium and salts thereof. Examples of vitamins include vitamin E, vitamin C, vitamin A, vitamin D, vitamins B, biotin and niacin. Examples of the excipient include dextrin, starch, lactose, crystalline cellulose and the like. Examples of the binder include polyvinyl alcohol, gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone and the like. Examples of the lubricant include magnesium stearate, calcium stearate, talc and the like. Examples of the disintegrant include crystalline cellulose, agar, gelatin, calcium carbonate, sodium hydrogen carbonate, dextrin and the like. Examples of the emulsifier or surfactant include sucrose fatty acid ester, citric acid, lactic acid, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, lecithin and the like. Examples of the base include cetostearyl alcohol, lanolin, polyethylene glycol and the like. Examples of the solubilizing agent include polyethylene glycol, propylene glycol, sodium carbonate, sodium citrate and the like. Examples of the suspending agent include glyceryl monostearate, polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxymethyl cellulose, sodium alginate and the like. These may be used alone or in combination of two or more.
眠気抑制用飲食品としては、例えば、水、清涼飲料水、果汁飲料、乳飲料、アルコール飲料、ノンアルコール飲料、スポーツドリンク、栄養ドリンク等の飲料、パン類、麺類、米類、豆腐、乳製品、醤油、味噌、菓子類等の食品が挙げられる。飲食品は、健康食品、特定保健用食品、機能性食品、栄養機能食品、サプリメント等の形態で提供されてもよい。 Examples of the drowsiness control food and drink include water, soft drinks, fruit juice drinks, milk drinks, alcoholic drinks, non-alcoholic drinks, sports drinks, nutritional drinks, and other beverages, breads, noodles, rice, tofu, and dairy products. , Soy sauce, miso, confectionery and the like. The food and drink may be provided in the form of health foods, foods for specified health uses, functional foods, nutritionally functional foods, supplements and the like.
以下、実施例により本発明を具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be specifically described with reference to examples, but the present invention is not limited to these examples.
＜被験者＞
被験者として、表１に示す年齢及び人数で構成された被験者群Ｘ及び被験者群Ｙを対象とした。
<Subject>
As test subjects, a test subject group X and a test subject group Y composed of the ages and the number of persons shown in Table 1 were used.
＜試験方法＞
被験者群Ｘにはそれぞれパラチノース２０ｇを約１８０ｍＬの水に溶解した飲料を、被験者群Ｙにはそれぞれグルコース２０ｇを約１８０ｍＬの水に溶解した飲料を摂取させた。飲料の摂取６０分前（−６０分）、摂取直後（０分）、摂取してから６０分後（６０分）、１２０分後（１２０分）、及び１８０分後（１８０分）に、認知機能検査（Cognitrax system）と併せて、下記評価基準に基づく眠気の程度に関するアンケートを実施した。
（評価基準）
１：眠気はない
２：普通
３：やや眠気がある
４：かなり眠気がある
<Test method>
Subject group X ingested a beverage in which 20 g of palatinose was dissolved in about 180 mL of water, and subject group Y ingested a beverage in which 20 g of glucose was dissolved in about 180 mL of water. Recognition 60 minutes before (-60 minutes), (0 minutes) after, 60 minutes (60 minutes), 120 minutes (120 minutes), and 180 minutes (180 minutes) after ingestion of the beverage. In addition to the functional test (Cognitrax system), a questionnaire regarding the degree of drowsiness based on the following evaluation criteria was conducted.
(Evaluation criteria)
1: Not sleepy 2: Normal 3: Somewhat sleepy 4: Very sleepy
被験者群Ｘ及びＹにおける、評価点の平均値及び標準偏差を表２に示す。また、飲料摂取６０分前の評価点の平均値を０点としたときの評価点の変化量（平均値±標準偏差）を併せて示す。 Table 2 shows the average values and standard deviations of the evaluation points in the subject groups X and Y. In addition, the change amount (average value±standard deviation) of the evaluation points when the average value of the evaluation points 60 minutes before the drink is taken is 0 is also shown.
＜統計解析＞
評価点及び変化量について、Ｍａｎｎ−ＷｈｉｔｎｅｙのＵ検定による統計解析を行った。結果を表２に示す。表２中、＊又は＊＊は−６０分における結果に対して有意差があることを示し（＊：ｐ＜０．０５、＊＊：ｐ＜０．０１）、＃＃は各時点での群間比較において有意差があることを示す（＃＃：ｐ＜０．０１）。
<Statistical analysis>
About an evaluation point and the amount of change, the statistical analysis by Mann-Whitney U test was performed. The results are shown in Table 2. In Table 2, * or ** indicates that there is a significant difference with respect to the result at -60 minutes (*: p<0.05, **: p<0.01), and ## indicates each time point. It shows that there is a significant difference in the comparison between groups (##: p<0.01).
Claims (2)
A food or drink for suppressing drowsiness, which contains isomaltulose as an active ingredient.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018214514A JP7316035B2 (en) | 2018-11-15 | 2018-11-15 | Drowsiness suppressant and food/beverage for suppressing drowsiness |
| PCT/JP2019/044426 WO2020100919A1 (en) | 2018-11-15 | 2019-11-12 | Sleepiness suppressant and food/beverage for suppressing sleepiness |
| KR1020217018202A KR20210091264A (en) | 2018-11-15 | 2019-11-12 | Drowsiness suppressants and food products for drowsiness suppression |
| CN201980075009.XA CN112996520A (en) | 2018-11-15 | 2019-11-12 | Drowsiness inhibitor and food and drink for inhibiting drowsiness |
| SG11202105004YA SG11202105004YA (en) | 2018-11-15 | 2019-11-12 | Sleepiness suppressant and food/beverage for suppressing sleepiness |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018214514A JP7316035B2 (en) | 2018-11-15 | 2018-11-15 | Drowsiness suppressant and food/beverage for suppressing drowsiness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020080650A true JP2020080650A (en) | 2020-06-04 |
| JP7316035B2 JP7316035B2 (en) | 2023-07-27 |
Family
ID=70730464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018214514A Active JP7316035B2 (en) | 2018-11-15 | 2018-11-15 | Drowsiness suppressant and food/beverage for suppressing drowsiness |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP7316035B2 (en) |
| KR (1) | KR20210091264A (en) |
| CN (1) | CN112996520A (en) |
| SG (1) | SG11202105004YA (en) |
| WO (1) | WO2020100919A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003034643A (en) * | 2001-05-14 | 2003-02-07 | Shin Mitsui Sugar Co Ltd | Composition for sustaining power of concentration and power of attention and food-and-drink containing the same |
| JP2009106253A (en) * | 2007-11-01 | 2009-05-21 | Unicafe Inc | Functional coffee having enhancing effect on motion endurance |
| US20130095125A1 (en) * | 2005-03-19 | 2013-04-18 | Bruce W. Kneller | Palatinose for enhancing dietary supplement and pharmaceutical delivery |
| JP2015221773A (en) * | 2014-05-23 | 2015-12-10 | 味の素株式会社 | Physiological effect promoter of caffeine |
| JP2017095500A (en) * | 2010-07-14 | 2017-06-01 | ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト | Isomaltulose for use in enhancing mental performance |
| CN107467463A (en) * | 2017-08-29 | 2017-12-15 | 江苏耐雀生物工程技术有限公司 | A kind of preparation method and application for antifatigue solid beverage of refreshing oneself |
| WO2018016110A1 (en) * | 2016-07-22 | 2018-01-25 | サントリーホールディングス株式会社 | Caffeine-containing colorless transparent drink |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011468D0 (en) * | 2000-05-13 | 2000-06-28 | Cerestar Holding Bv | Method for enzymatically hydrolysing mixtures of isomaltulose and trehalulose |
| JP5620647B2 (en) | 2009-01-30 | 2014-11-05 | ハウス食品グループ本社株式会社 | Sleepiness alarm composition |
| CN104846036A (en) * | 2015-06-02 | 2015-08-19 | 山东绿健生物技术有限公司 | Isomaltulose preparation method |
-
2018
- 2018-11-15 JP JP2018214514A patent/JP7316035B2/en active Active
-
2019
- 2019-11-12 KR KR1020217018202A patent/KR20210091264A/en active Search and Examination
- 2019-11-12 WO PCT/JP2019/044426 patent/WO2020100919A1/en active Application Filing
- 2019-11-12 SG SG11202105004YA patent/SG11202105004YA/en unknown
- 2019-11-12 CN CN201980075009.XA patent/CN112996520A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003034643A (en) * | 2001-05-14 | 2003-02-07 | Shin Mitsui Sugar Co Ltd | Composition for sustaining power of concentration and power of attention and food-and-drink containing the same |
| US20130095125A1 (en) * | 2005-03-19 | 2013-04-18 | Bruce W. Kneller | Palatinose for enhancing dietary supplement and pharmaceutical delivery |
| JP2009106253A (en) * | 2007-11-01 | 2009-05-21 | Unicafe Inc | Functional coffee having enhancing effect on motion endurance |
| JP2017095500A (en) * | 2010-07-14 | 2017-06-01 | ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト | Isomaltulose for use in enhancing mental performance |
| JP2015221773A (en) * | 2014-05-23 | 2015-12-10 | 味の素株式会社 | Physiological effect promoter of caffeine |
| WO2018016110A1 (en) * | 2016-07-22 | 2018-01-25 | サントリーホールディングス株式会社 | Caffeine-containing colorless transparent drink |
| CN107467463A (en) * | 2017-08-29 | 2017-12-15 | 江苏耐雀生物工程技术有限公司 | A kind of preparation method and application for antifatigue solid beverage of refreshing oneself |
Non-Patent Citations (1)
| Title |
|---|
| JUN KASHIMURA ET.AL: "The Effect of Palatinose on Mental Concentration in Humans", JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, vol. 49, JPN6022034077, 2003, pages 214 - 216, XP008129518, ISSN: 0004976658 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210091264A (en) | 2021-07-21 |
| JP7316035B2 (en) | 2023-07-27 |
| WO2020100919A1 (en) | 2020-05-22 |
| CN112996520A (en) | 2021-06-18 |
| SG11202105004YA (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2823306C (en) | Combination of components for the prevention and treatment of frailty | |
| US20110256299A1 (en) | Nutritional Powders Comprising Spray Dried HMB | |
| TWI722992B (en) | Brain function improving agent, and preventive or therapeutic agent for cognitive dysfunction | |
| JPH1179987A (en) | Composition for suppressing accumulation of hepatic fat and food additive for suppressing accumulation of hepatic fat | |
| JP2012126683A (en) | Composition for sympathetic activation | |
| JP7316035B2 (en) | Drowsiness suppressant and food/beverage for suppressing drowsiness | |
| US20100093657A1 (en) | Low glycemic mixtures | |
| JP7090849B2 (en) | Liver function improving composition and liver function improving food composition | |
| JP2009013143A (en) | Sleep-improving composition | |
| TWI796560B (en) | Composition for promoting GLP-1 secretion | |
| WO2020218383A1 (en) | Glp-1 secretagogue | |
| JP7373918B2 (en) | Composition for regulating skin gas diffusion | |
| TW202106310A (en) | Composition for promoting GLP-1 secretion | |
| JP2006160697A (en) | Sleep-related health ameliorative agent | |
| JP7305595B2 (en) | Agent for improving mental fatigue, decreased motivation or drowsiness | |
| JP2015529470A (en) | Composition containing β-hydroxy-β-methylbutyric acid (METHYLBUTRYICACID) and use thereof | |
| JP2020026395A (en) | Anti-i type allergic agent | |
| WO2024029620A1 (en) | Cerebral blood flow augmenter, brain activity promoter, and wakefulness improver | |
| JP4831540B2 (en) | Oral hypnotics and hypnotic foods and drinks | |
| JP2006137746A (en) | Orexin-inducing composition | |
| JP4405308B2 (en) | Alcohol absorption inhibitor | |
| US20200205456A1 (en) | Nutritional tablets and methods of making the same | |
| JP2023021088A (en) | Autonomic nerve regulator and cognitive function improver | |
| JP2020026394A (en) | Antihypertensive | |
| KR20210003716A (en) | Exocrine promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20210531 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230501 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230512 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230711 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230714 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7316035 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |